Meet with... Angel Investors
JLABS @ LabCentral , 700 Main Street , Cambridge , MA
February 25, 2016 from 11:30 AM to 14:00 PM (EDT)
$10 - $35
Looking for an angel? ...Confused about the process? ...Overwhelmed by the diversity of angel investors? You're not alone. JLABS is bringing together a cohort of angel investors to speak with the early-stage life sciences community to help you get ahead when it comes to angel money.
Angel investors will be presenting on Thursday, February 25. They will offer insights, lessons learned, and best practices for seeking angel money. You'll also learn about the differences between these networks, as well as the key differences between angel investing and traditional venture funding.
For those companies who apply online and receive advance approval, one-on-one meetings with angel investors will provide a private forum to discuss your company.
10:30am | Registration Opens and Networking
11:00am | Presentations
12:00pm | Panel Discussion
12:30pm | Networking Lunch
1:00-4:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on February 9th.
Richard Anders | Founder, Executive Director, Mass Medical Angels read bio»
Eyal Geffen | Managing Partner, Sky Ventures read bio»
Deb Kemper | Managing Director, Golden Seeds read bio»
Yaniv Sneor | Founder, Mid Atlantic BioAngels read bio»
[moderator] Marian Nakada | Vice President, Venture Investments, Johnson & Johnson Innovation - JJDC read bio»
About Mass Medical Angels:
Mass Medical Angels (MA2) is a seed stage investor group exclusively focused on life science and healthcare investments. Our mission is to bring more clinical tools to the marketplace, while attaining superior returns for our investors. To do this, we provide financing and mentoring to early-stage life-science companies so that they can obtain further funding, reach positive cash-flows or get acquired. MA2 members are carefully vetted for their deep expertise around the health sciences. Many of them have been researchers, clinicians, venture capitalists, executives, consultants, engineers, bankers or attorneys. They bring a willingness to support early stage companies to further our mission. In addition, we draw on our deep relationships with the institutions in Boston healthcare supercluster, the leading healthcare innovation center in the world. They provide additional resources, including deal flow, expertise and advisors for the companies we work with.
MA2 provides early stage funding to companies looking to raise between $250K to $3MM. Depending on the size of the investment, MA2 is willing to provide all or part of a round. We are willing to work closely with other angel groups or venture funds to ensure that the round is closed and a company adequately capitalized. We are looking for companies that are extremely capital efficient and where our funds will lead to significant step-ups in valuation (in part to avoid unfavorable future funding rounds). Our target is a 5x return within 5 years.
We invest in medical devices, therapeutics, diagnostics, health services, health information technologies, and relevant research-related tools including laboratory equipment.
Mass Medical Angels' Participating Representative: Richard Anders, J.D. | Founder, Executive Director, Mass Medical Angels
Richard Anders is is an investor and long-time entrepreneur. He founded the legal software publishing company Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry and currently serves as managing director of Rubin/Anders Scientific, which places scientists as consultants in patent projects. He has invested in approximately two dozen early-stage startups. Richard is a long-time trustee of the Museum of Science in Boston, where he is a member of the food committee, exploring science education around the issues of food and its preparation, a trustee of the Forsyth Institute and an overseer at the Brigham & Women's Hospital and the Gardner Museum. Richard founded and currently runs MA Medical Angels (MA2), one of the country's leading angel groups focused exclusively on life sciences. He has founded the angel group Launchpad, the nationally renowned Science on Screen event at the Coolidge Corner Cinema and was a founding trustee of the Massachusetts Interactive Media Council. He served for many years as a member of the Dana Farber Cancer Center Institutional Review Board. He is a board observer at Avaxia Biologics and Siamab. Richard teaches medical device entrepreneurship at the Harvard/MIT HST program. He is a graduate Summa Cum Laude in Mathematics from Harvard and holds a J.D. from Harvard Law School.
Connect with Richard:
About Sky Ventures:
Sky Ventures Group provides startups with access to the world's leading healthcare and life science investors. Our unique investment approach combines the best features of early stage funding and strategic partnerships. Among our members are qualified investors who have extensive experience building and running new ventures, as well as strategic partners from leading corporations and institutions. While we recognize that capital plays a major role, we also understand that a strategic approach is essential to every venture success.
Sky Ventures' Participating Representative: Eyal Geffen | Managing Partner, Sky Ventures
Eyal Geffen has 15 years of demonstrated success in various management and hands on positions. He has had experience with large corporations, coupled with extensive background building and running new ventures and comprehensive knowledge of international markets. As a founder and Managing Partner of Sky Ventures Group, Eyal is responsible for all management and day to day operations.
Connect with Eyal:
About Golden Seeds:
It is well documented: Women are starting businesses at record levels, with the ideas, skills and talents to build great companies. But like all early-stage entrepreneurs, they need capital to fuel their growth. Golden Seeds, one of the nation's largest and most active investment groups, focuses squarely on this high-potential segment.
Our investment thesis rests on the extensive research that concludes that gender diverse teams produce better return on equity. By seeking companies where women hold leadership positions and own substantial equity, we are funding companies that are likely to have diverse perspectives that will contribute to ultimate success.
Since 2005, Golden Seeds' members - today over 275 strong - along with its venture funds, have invested over $70 million in more than 65 exciting women-led enterprises…and counting. Headquartered in New York City, Golden Seeds also has chapters in Boston, Silicon Valley, Southern California (SoCal) and Texas - and active members throughout the country.
Golden Seeds' Participating Representative: Deb Kemper | Managing Director, Golden Seeds
Deb Kemper is an active angel investor and currently leads the Boston Forum for Golden Seeds, a national angel network. She focuses on ventures in clean tech, healthcare, and technology. Previously, Deb worked at McKinsey, where she served clients in the electronics, energy, and health care sectors. Her functional experience includes manufacturing, product development, operations, strategy, professional development, and leadership coaching. She has provided leadership support to organizations in China, Peru and the United States, recently working with JUCCCE, a non-profit sustainability think tank in China. She has a BS in Engineering from Cornell and an MBA from The Tuck School of Business at Dartmouth, where she was named an Edward Tuck Scholar. Deb recently returned to the US after 8 years living in Peru and China.
Connect with Deb:
About Mid Atlantic BioAngels:
Mid Atlantic BioAngels group (MABA), is an angel investor group focused exclusively on new and emerging life science companies. Membership in MABA is by invitation only, and is extended to active, accredited investors (life science angels) who wish to make investments in life science companies, as well as institutional investors and life science company venture arms wishing to invest alongside the angels.
MABA places no geographical restrictions or requirements for presenting companies, as long as meaningful and effective post-investment monitoring of these companies can be achieved.
Mid Atlantic BioAngels' Participating Representative: Yaniv Sneor | Founder, Mid Atlantic BioAngels
Yaniv Sneor is a (reformed) physicist, who made the transition into the business world after being bitten by the entrepreneurial bug. Yaniv is one of the founders of MABA – Mid Atlantic Bio Angels (bioangels.net) a life science angel investor group. MABA also orchestrates regular life science pitching events (1stpitchlifescience.com), which began in NYC and have since expanded to other states. Yaniv has been involved in founding, growing, managing and re-engineering companies for the past 25+ years, in multiple industries. He ran companies of different sizes and at different life-stages, led re-structuring activities, purchased and sold multiple companies, and negotiated and integrated joint ventures and strategic relationships. Through his consulting practice (Blue Cactus Consulting), Mr. Sneor assists companies with strategy, execution and technology commercialization.
Connect with Yaniv:
Marian Nakada, Ph.D. | Vice President, Venture Investments, Johnson & Johnson Innovation - JJDC
Marian is a Vice President in Venture Investments at Johnson & Johnson Development Corporation, and is based in the Johnson & Johnson Innovation Center in Boston. She focuses primarily on pharmaceuticals (small molecules and biologics) and diagnostics.
Previously, Marian was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson's Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy.
Marian joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Marian joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor's technologies were competitive with the industry.
Marian has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.
Connect with Marian:
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on February 24th (or sold out).
FREE | Application
FREE | Accepted Companies
*Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on February 9th. Your application will be reviewed by each participating angel investor and you will be notified of acceptance by any or all participating networks on February 17th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
JLABS @ LabCentral
700 Main Street